stonks4u
Sign up free
EMMA logo

EMMA Emmaus Life Sciences, Inc.

Other OTC · Biotechnology · Healthcare

$0.01
+0.00 (+0.00%)

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with si…

Market Cap: $807.2Kwww.emmausmedical.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 14Aug 14

Quote

Day Range
$0.01 – $0.01
52-Week Range
$0.01 – $0.02
Volume
$120.0K
Market Cap
$807.2K
50-Day Avg
$0.01
200-Day Avg
$0.01
Prev Close
$0.01
Open
$0.01

Valuation & Ratios

P/E Ratio
-0.11
EPS
$-0.12
P/B Ratio
-0.01
P/S Ratio
0.07
Debt/Equity
-0.51
Current Ratio
0.11
Dividend Yield
+0.0%
Gross Margin
+93.1%

Returns & Efficiency

Return on Equity
+11.8%
Return on Assets
-35.0%
FCF Yield
-1.4%
EV/EBITDA
-100.85

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$12.45M$-7.49M$-0.12
2024$16.65M$-6.45M$-0.10
2023$29.60M$-3.73M$-0.07
2022$18.39M$-10.63M$-0.21
2021$20.61M$-15.95M$-0.32

Social Signal Score

50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

2of 5 quarters beat consensus

Typical surprise -200.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Fri, Aug 14$0.02 vs $-0.06beat
  • Fri, May 15$-0.05 vs $-0.06beat
  • Mon, Mar 30$-0.03 vs $0.01miss
  • Mon, Apr 14$-0.03 vs $0.01miss
  • Tue, Nov 19$-0.01 vs $0.01miss

Estimates and results for EMMA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

EMMAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsbusinesswire.com·22h ago·Neutral

    Emmaus Life Sciences Reports Quarterly Financial Results TORRANCE, Calif.--(BUSINESS WIRE)--Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. Highlights “Under our previously announced License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effect…

    View source ↗